Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: A cocktail analysis

European Journal of Clinical Pharmacology

Volumn 66, Issue 1, 2010, Pages 67-76

  Jenkins, Julian ^a   Williams, Daphne ^a   Deng, Yanli ^a   Collins, David A ^a   Kitchen, Valerie S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

CYP1A2; CYP2C19; CYP2C9; CYP3A4; Eltrombopag

Indexed keywords

4 HYDROXYFLURBIPROFEN; 5 HYDROXYOMEPRAZOLE; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; ELTROMBOPAG; FLURBIPROFEN; LOSEC MUPS; MIDAZOLAM; OMEPRAZOLE; PARAXANTHINE; PROPLUS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DROWSINESS; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ENZYME ACTIVITY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BENZOIC ACIDS; CAFFEINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLURBIPROFEN; HUMANS; HYDRAZINES; ISOENZYMES; MALE; MIDAZOLAM; OMEPRAZOLE; PHARMACEUTICAL PREPARATIONS; PYRAZOLES; RECEPTORS, THROMBOPOIETIN;

EID: 76949088983     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0716-6     Document Type: Article

References (26)

1. DJ Kuter CG Begley 2002 Recombinant human thrombopoietin: basic biology and evaluation of clinical studies Blood 100 3457 3469 10.1182/blood.V100.10. 3457 1:CAS:528:DC%2BD38XoslKmtL0%3D 12411315 (Pubitemid 35303910)
2. K Kaushansky 1995 Thrombopoietin: the primary regulator of platelet production Blood 86 419 431 1:CAS:528:DyaK2MXmvVyht7c%3D 7605981
3. B Wang JL Nichol JT Sullivan 2004 Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand Clin Pharm Ther 76 628 638 10.1016/j.clpt.2004.08.010 1:CAS:528:DC%2BD2cXhtVKlt7vJ (Pubitemid 39601552)
4. Kuter D, Bussel J, George J et al (2006) Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Blood 108: Abstract 476
5. CL Erickson-Miller E Delorme L Giampa, et al. 2004 Biological activity and selectivity for TPO receptor of the orally bioavailable, small molecule TPO receptor agonist, SB-497115 Blood 104 2912a 10.1182/blood-2003-05-1669 (Pubitemid 39434979)
6. T Sellers T Hart M Semanik K Murthy 2004 Pharmacology and safety of SB-497115-GR, an orally active small molecular weight TPO receptor agonist, in chimpanzees, rats and dogs Blood 104 2063a
7. JM Jenkins D Williams Y Deng J Uhl V Kitchen D Collins CL Erickson-Miller 2007 Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist Blood 109 4739 4741 10.1182/blood-2006-11-057968 1:CAS:528:DC%2BD2sXmt1Ogtb0%3D 17327409 (Pubitemid 46827766)
8. JB Bussel G Cheng MN Saleh, et al. 2007 Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura N Engl J Med 357 2237 2247 10.1056/NEJMoa073275 1:CAS:528:DC%2BD2sXhsVSmtL%2FP 18046028 (Pubitemid 350190754)
9. JG McHutchison G Dusheiko ML Shiffman, et al. 2007 TPL102357 Study Group Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C N Engl J Med 357 2227 2236 10.1056/NEJMoa073255 1:CAS:528: DC%2BD2sXhsVSmt7fE 18046027 (Pubitemid 350190753)
10. C Erickson-Miller E Delorme SS Tian, et al. 2008 Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietic growth factor Stem Cells 27 424 430 10.1634/stemcells.2008-0366
11. DW Nebert DW Russell 2002 Clinical importance of the cytochromes P450 Lancet 360 1155 1162 10.1016/S0140-6736(02)11203-7 1:CAS:528: DC%2BD38XnvVKjt7g%3D 12387968 (Pubitemid 35246494)
12. MC Jerdi Y Daali MK Oestreicher S Cherkaoui P Dayer 2004 A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes J Pharm Biomed Anal 35 1203 1212 10.1016/j.jpba.2004.03.021 1:CAS:528:DC%2BD2cXntFSmtLs%3D 15336365 (Pubitemid 39140285)
13. JY Ryu IS Song YE Sunwoo JH Shon KH Liu IJ Cha JG Shin 2007 Development of the "Inje cocktail" for high-throughput of five human cytochrome P450 isoforms in vivo Clin Pharm Ther 82 531 540 10.1038/sj.clpt.6100187 1:CAS:528:DC%2BD2sXhtF2qsL7O (Pubitemid 47622519)
14. NK Zgheib RF Frye TS Tracy M Romkes RA Branch 2006 Validation of incorporating flurbiprofen into the Pittsburgh cocktail Clin Pharmacol Ther 80 257 263 10.1016/j.clpt.2006.06.005 1:CAS:528:DC%2BD28XptFCgu7k%3D 16952492 (Pubitemid 44313908)
15. NK Zgheib RF Frye TS Tracy M Romkes RA Branch 2007 Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity Br J Clin Pharmacol 63 477 487 10.1111/j.1365-2125.2006.02781.x 1:CAS:528: DC%2BD2sXlt1ahu78%3D 17054666 (Pubitemid 46426631)
16. M Christensen K Andersson P Dalén, et al. 2003 The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes Clin Pharmacol Ther 73 517 528 10.1016/S0009-9236(03)00050-X 1:CAS:528:DC%2BD3sXkt1Ortbw%3D 12811361 (Pubitemid 37249122)
17. N Poolsup A Li Wan Po TL Knight 2000 Pharmacogenetics and psychopharmacotherapy J Clin Pharm Ther 25 197 220 10.1046/j.1365-2710.2000. 00281.x 1:CAS:528:DC%2BD3cXlvFyqt7g%3D 10886465 (Pubitemid 30495312)
18. PAHM Wijnen RAM Op Den Buijsch M Drent, et al. 2007 Review article: the prevalence and clinical relevance of cytochrome P450 polymorphisms Aliment Pharmacol Ther 26 Suppl 2 211 219 1:CAS:528:DC%2BD1cXot12jtQ%3D%3D 18081664
19. S Chainuvati AN Nafziger JS Leeder A Gaedigk GL Kearns E Sellers Y Zhang AD Kashuba E Rowland JS Bertino Jr 2003 Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail" Clin Pharmacol Ther 74 437 447 10.1016/S0009-9236(03)00229-7 1:CAS:528:DC%2BD3sXos1CjtbY%3D 14586384 (Pubitemid 37357722)
20. LA McLaughlin MJ Paine CA Kemp JD Maréchal CJ Ward MJ Stcliffe GC Roberts CR Wolf 2005 Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding J Biol Chem 280 38617 38624 10.1074/jbc.M505974200 1:CAS:528:DC%2BD2MXht1SktLvJ 16162505 (Pubitemid 43853763)
21. DS Streetman JF Bleakley JS Kim AN Nafziger JS Leeder A Gaedigk R Gotschall GL Kearns JS Bertino Jr 2000 Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the 'Cooperstown cocktail' Clin Pharmacol Ther 68 375 383 10.1067/mcp.2000.109519 1:CAS:528:DC%2BD3cXot1Wjsbc%3D 11061577 (Pubitemid 30803526)
22. RF Yeh VE Gaver KB Patterson NL Rezk F Baxter-Meheux MJ Blake JJ Eron Jr CE Klein JC Rublein AD Kashuba 2006 Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers J Acquir Immune Defic Syndr 42 52 60 1:CAS:528:DC%2BD28XlsFGqtrY%3D 16639344
23. V Ozdemir W Kalow BK Tang AD Paterson SE Walker L Endrenyi AD Kashuba 2000 Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method Pharmacogenetics 10 373 388 10.1097/00008571-200007000-00001 1:CAS:528:DC%2BD3cXlt1yjs78%3D 10898107 (Pubitemid 30433571)
24. SA Wrighton BJ Ring PB Watkins M VandenBranden 1989 Identification of a polymorphically expressed member of the human cytochrome P-450III family Mol Pharmacol 36 97 105 1:CAS:528:DyaK3cXhtFKiurc%3D 2747634 (Pubitemid 19191265)
25. JC Kolars WM Awni RM Merion PB Watkins 1991 First-pass metabolism of cyclosporin by the gut Lancet 338 1488 1490 10.1016/0140-6736(91)92302-I 1:STN:280:DyaK38%2FnvFGrtQ%3D%3D 1683920
26. KE Thummel DD Shen TD Podoll, et al. 1994 Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation J Pharmacol Exp Ther 271 557 566 1:CAS:528:DyaK2MXhvVyqu7Y%3D 7965756